

Genetic Informed Consent Form Template

Genetic Research Studies

In genetic research there are potential health, legal, societal, and emotional issues to consider. Often, the genetic testing is a sub-study of a much larger study. It is important that the issues related to genetic testing not get lost in the body of a consent form, which describes the main portion of the study. Thus you need to use a separate consent form or an addendum to the consent form. You can find an example form in Deschenes M. Cardinal G. Knoppers BM, Glass KC (2001).

- The investigator should supply the following information in ordinary language, avoiding jargon and supplying explanations (in lay terms) for crucial terms.
- The form must be in the 2nd person (i.e. you), and should be phrased in a tone that is respectful to participants (e.g. participants should be *asked* to return for a final visit, participants who become pregnant during the study should be asked permission to follow the pregnancy.)
- You must include a footer that contains the following information: version number and date, a place for participant initials, and page numbers.
- This is a template, so if any item is obviously irrelevant, it need not be included.
- You must put this document on your letterhead.
- Please ensure the headings are in the order presented here.

Note: The CTC will not review the protocol unless it meets **all** mandatory and verbatim requirements. Once you add these sections to your Genetic Informed Consent, please delete any redundant/duplicate clauses.

1. This first page of the informed consent form must begin with the following:

Mandatory and Verbatim:

Research Project and Title:		
Investigator(s):		
Sponsor:		
This consent form, a copy of which has been given to you, is only part of the process of informed consent. It should give you the basic idea of what the research is about and what your participation will involve. If you would like more detail about something mentioned here, or information not included here, you should feel free to ask. Please take the time to read this carefully and to understand any accompanying information.		

2. **Purpose of the Genetic Research**: this section should, in lay terms, reflect the primary genetic objective(s) of the study, as contained in the protocol.

Version date June 2017 pg. 1 of 6

3. Procedures

This section should provide a detailed description of what participation will entail for the research participant, referring only to the genetic portion of the study.

4. Voluntary Participation

Include information regarding the provision of ongoing care for participants who are screen failures; withdrawals for any reason; or participants who complete the study. Indicate that there are no negative consequences for the participant if they choose not to participate, including access to standard care.

5. Risks and Discomforts

- physical, psychological, social, economic
- Please note that the risk of individual harm arising from participating in genetic research is unclear. Inclusion of the following paragraph may offer some clarity but you should only insert it IF it reflects what you and the sponsor are actually doing. Otherwise, the paragraph could be modified, as needed, to reflect the reality:

"There may be risks to your eligibility for employment, life insurance, mortgage insurance or private health insurance if the results of genetic testing were to be inadvertently disclosed to certain parties. Safeguards have been established to ensure that such disclosure will not occur. For example, we have taken steps to ensure that a coded number, rather than your name, will be used to identify your sample and that your name will not be disclosed in association with the sample at any time. In addition, the results of genetic testing will not be placed in your medical record. Despite these efforts, however, we cannot guarantee you with 100% certainty that your genetic information could never be linked to you."

Rationale: the risk of individual harm arising from participating in genetic research is unclear. Inclusion of the preceding paragraph may offer some clarity but should only be inserted IF it reflects what you and the sponsor are actually doing. Otherwise, the paragraph could be modified as needed to reflect the reality.

6. Benefits

This section should explain the probability and nature of direct and indirect benefits to the participants and to others. Although not mandatory, the following statement is recommended, "Although participation in this study may be of no benefit to you personally, it is hoped that what is learned here will be of future benefit to others suffering from disease X." Items such as close physician monitoring and the free provision of medications and services may be seen by some participants as inducements to participate and therefore, must not be listed as a benefit.

7. Confidentiality

- Sample storage (identification, location, length of storage, safeguards to protect privacy, withdrawal of sample, unlinking/anonymization procedure, sample destruction)
- Disclosure of results to the participant, family members, third parties
- This section should be relevant to genetic information only

8. Commercialization

A statement/explanation that the participant has given up his/her right to share in potential commercial benefits

Version date June 2017 pg. 2 of 6

9. **Tiered Consent** (examples, not exhaustive) (if applicable)

- Permitting coded* use of their biological materials for the proposed study only, with no further contact permitted to ask for permission to do further studies,
- Permitting coded use of their biological materials for the proposed study only, with further contact permitted to ask for permission to do further studies,
- Permitting coded use of their biological materials for any study relating to the condition for which the sample was originally collected, with further contact allowed to seek permission for other types of studies,
- Permitting coded use of their biological materials for the proposed study only and anonymized use for any kind of future study,
- Permitting only anonymized (unlinked) use of their biological materials in research,
 *coded = identifiable, traceable. Biological materials that are unidentified for research purposes but can be linked to their sources through the use of a code.

10. Signature Page

Although the investigator can delegate the provision of information for the consent, the investigator retains ultimate legal and ethical responsibility for ensuring the participant:

- a. is provided with all appropriate information (for each individual participant);
- b. understands the information;
- c. has had all questions adequately addressed; and
- d. has the capacity to consent.

The last page of the informed consent form must end with the following:

Version date June 2017 pg. 3 of 6

Mandatory and Verbatim:

Your signature on this form indicates that you have understood to your satisfaction the information regarding participation in the research project and agree to participate as a participant. In no way does this waive your legal rights nor release the investigators, sponsors, or involved institutions from their legal and professional responsibilities. You are free to withdraw from the study at any time without jeopardizing the health care you are entitled to receive. Your continued participation should be as informed as your initial consent. You will be informed in a timely manner if information becomes available that may affect your willingness to continue participating in this study. You should also feel free to ask for clarification or new information throughout your participation. If you have further questions concerning matters related to this research, please contact:

(Name of responsible investigator(s))	Phone number			
Dr will be receiving final protocol for your participation in this study.	ancial compensation from the sponsors of this research			
If you have questions concerning your rights as a possible participant in this research, please contact the Office of the Health Research Ethics Board of Alberta – Clinical Trials Committee at: 780-423-5727 or toll-free at 1-877-423-5727.				
Participant's name (please print)	 			
Participant's signature				
Investigator's name (please print)				
Investigator's signature				
Delegate's name (please print) (Optional)	Date			
Delegate's signature (Optional)				
Witness' name (please print) (Optional)				
Witness' signature (Optional)				
We have given you a copy of this form to keep for your records and reference.				
For inclusion in pediatric studies only add: The investigator will, as appropriate, explain the nature of the research to your child and his or her				

Version date June 2017 pg. 4 of 6

involvement in it, and will seek his or her ongoing cooperation throughout the project.

11. The following is required for inclusion only in studies where incompetent participants are recruited and who may become competent at a later date:

may become competent at a later date.				
Mandatory and Verbatim:				
PARTICIPANT'S ACCEPTANCE OF THIRD PARTY AUTHORIZATION Because your illness (or injury) made it impossible for you to participate in the in party authorization (e.g. family member) was obtained on your behalf. Your surreshed to participate in this research if you had been able to express your own of research.	rogate believed you would have			
The process of informed consent must be continuous throughout the research pr the right to change your mind and, therefore, must be given opportunities to read questions and then agree or disagree with the decision made by your surrogate to project.	d relevant consent materials, ask			
If you agree with the decision made by your surrogate to enroll you, your signatu in this study. If you do not agree with the decision made by your surrogate to enat any other time from the study.				
Your signature on this form indicates that you have understood to your satisfaction participation in the research project and agree to participate as a participant.	on the information regarding			
In no way does this waive your legal rights nor release the investigators, sponsors, or involved institutions from their legal and professional responsibilities. You are free to withdraw from the study at any time without jeopardizing the health care you are entitled to receive. Your continued participation should be as informed as your initial consent. You will be informed in a timely manner if information becomes available that may affect your willingness to continue participating in this study. You should also feel free to ask for clarification or new information throughout your participation.				
Please check the appropriate boxes to indicate your decision:				
☐ Agree with your surrogate's decision. ☐ Wish to remain in the	study.			
☐ Do not agree with your surrogate's decision. ☐ Wish to withdraw from	n the study.			
Participant's name (please print)				
Participant's signature	Date			
Investigator's name (please print)				
Investigator's signature	Date			
Delegate's name (please print) (Optional)	Date			
Delegate's signature(Optional)				
Witness' name (please print)	 Date			

Version date June 2017 pg. 5 of 6

Witness' signature (Optional)

A copy of this form has been given to you to keep for your records and reference.

Version date June 2017 pg. 6 of 6